Key Points
- CAO Jennifer Mak sold 1,500 shares on March 2 at an average price of $573.45 for total proceeds of $860,175, reducing her stake by 10.92% to 12,240 shares valued at about $7.02M.
- Axon beat quarterly expectations, reporting $2.15 EPS versus $1.60 expected and revenue of $796.72M (up 38.5% YoY); the stock carries a market cap of $45.8B and a high P/E of ~375.
- Analyst sentiment is largely positive, with 16 Buy and 3 Hold ratings and an average price target of $762.93 (consensus "Moderate Buy").
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CAO Jennifer Mak sold 1,500 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the sale, the chief accounting officer directly owned 12,240 shares in the company, valued at approximately $7,019,028. The trade was a 10.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Axon Enterprise Stock Performance
NASDAQ AXON opened at $569.81 on Thursday. The business has a fifty day moving average of $536.69 and a 200-day moving average of $620.70. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The stock has a market cap of $45.81 billion, a price-to-earnings ratio of 374.88, a price-to-earnings-growth ratio of 12.36 and a beta of 1.46. Axon Enterprise, Inc has a fifty-two week low of $396.41 and a fifty-two week high of $885.91.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. During the same quarter in the previous year, the business earned $2.08 earnings per share. The business's revenue for the quarter was up 38.5% on a year-over-year basis. As a group, analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Axon Enterprise
Hedge funds and other institutional investors have recently modified their holdings of the company. Westside Investment Management Inc. increased its holdings in shares of Axon Enterprise by 4.8% in the 2nd quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company's stock worth $225,000 after acquiring an additional 13 shares during the period. Newbridge Financial Services Group Inc. grew its position in Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company's stock worth $421,000 after purchasing an additional 14 shares during the last quarter. Vicus Capital increased its stake in shares of Axon Enterprise by 3.7% in the third quarter. Vicus Capital now owns 396 shares of the biotechnology company's stock valued at $284,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC raised its holdings in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock valued at $342,000 after buying an additional 15 shares during the last quarter. Finally, STF Management LP boosted its position in shares of Axon Enterprise by 1.4% during the second quarter. STF Management LP now owns 1,164 shares of the biotechnology company's stock worth $964,000 after buying an additional 16 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on AXON shares. Morgan Stanley dropped their price target on shares of Axon Enterprise from $713.00 to $675.00 and set an "overweight" rating for the company in a research report on Wednesday, February 25th. Northcoast Research raised Axon Enterprise from a "neutral" rating to a "buy" rating and set a $742.00 price target on the stock in a research report on Tuesday, January 6th. Barclays decreased their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an "overweight" rating for the company in a report on Wednesday, February 25th. TD Cowen reissued a "buy" rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Axon Enterprise from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise presently has an average rating of "Moderate Buy" and an average target price of $762.93.
View Our Latest Stock Analysis on Axon Enterprise
Axon Enterprise Company Profile
(
Get Free Report)
Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.
Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
